[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013031056A2 - peptídeos de sema5b e vacinas incluindo os mesmos - Google Patents

peptídeos de sema5b e vacinas incluindo os mesmos

Info

Publication number
BR112013031056A2
BR112013031056A2 BR112013031056A BR112013031056A BR112013031056A2 BR 112013031056 A2 BR112013031056 A2 BR 112013031056A2 BR 112013031056 A BR112013031056 A BR 112013031056A BR 112013031056 A BR112013031056 A BR 112013031056A BR 112013031056 A2 BR112013031056 A2 BR 112013031056A2
Authority
BR
Brazil
Prior art keywords
peptides
sema5b
polynucleotides
vaccines
above mentioned
Prior art date
Application number
BR112013031056A
Other languages
English (en)
Inventor
Gaku Nakayama
Ryuji Osawa
Sachiko Yoshimura
Takuya Tsunoda
Tomohisa Watanabe
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BR112013031056A2 publication Critical patent/BR112013031056A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

resumo patente de invenção: "peptídeos de sema5b e vacinas incluindo os mesmos". a presente invenção refere-se a peptídeos de epitopo isolados derivados de sema5b se ligam a um antígeno hla e induzem linfócitos t citotóxicos (ctl) e então são adequados para uso no contexto de imunoterapia de câncer, mais particularmente vacinas para câncer. os peptídeos da invenção compreendem ambas as sequências de aminoácido mencionadas acima e suas versões modificadas, onde um, dois ou vários aminoácidos são substituídos, deletados, inseridos ou adicionados, contanto que tal versão modificada retenha a ligação a hla e/ou capacidade de indução de ctl requerida das sequências originais. são ainda providos polinucleotídeos codificando qualquer um dos peptídeos mencionados acima bem como agentes ou composições farmacêuticos que incluem qualquer um dos peptídeos ou polinucleotídeos acima mencionados. os peptídeos, polinucleotídeos, agentes ou composições farmacêuticos da invenção encontram utilidade particular no tratamento e/ou prevenção de cânceres e tumores, incluindo, por exemplo, câncer de esôfago, nsclc, rcc e sclc.
BR112013031056A 2011-06-10 2012-06-07 peptídeos de sema5b e vacinas incluindo os mesmos BR112013031056A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161495819P 2011-06-10 2011-06-10
PCT/JP2012/003740 WO2012169200A1 (en) 2011-06-10 2012-06-07 Sema5b peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
BR112013031056A2 true BR112013031056A2 (pt) 2016-11-29

Family

ID=47295783

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031056A BR112013031056A2 (pt) 2011-06-10 2012-06-07 peptídeos de sema5b e vacinas incluindo os mesmos

Country Status (14)

Country Link
US (1) US9187556B2 (pt)
EP (1) EP2718435A4 (pt)
JP (1) JP2014519311A (pt)
KR (1) KR20140026543A (pt)
CN (1) CN103620033A (pt)
AU (1) AU2012265677A1 (pt)
BR (1) BR112013031056A2 (pt)
CA (1) CA2838633A1 (pt)
IL (1) IL228995A0 (pt)
MX (1) MX2013014489A (pt)
RU (1) RU2013158399A (pt)
SG (1) SG195047A1 (pt)
TW (1) TW201302800A (pt)
WO (1) WO2012169200A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015007015A (es) * 2012-12-04 2015-09-28 Oncotherapy Science Inc Peptidos sema5b y vacunas que contienen los mismos.
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (zh) * 2015-03-31 2022-08-01 德商英麥提克生物技術股份有限公司 用於腎細胞癌(rcc)免疫治療的新型肽和肽組合物和支架
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
EP4029494A1 (en) 2017-01-25 2022-07-20 OSE Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
KR102659285B1 (ko) * 2020-08-11 2024-04-22 경북대학교 산학협력단 암세포 유래 엑소좀에 선택적으로 결합하는 펩타이드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074237A2 (en) 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CN101278059A (zh) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 诊断和治疗肾细胞癌的方法
EP1907580A2 (en) * 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2008093982A1 (en) * 2007-01-29 2008-08-07 Procell Therapeutics Inc. Novel macromolecule transduction domains and methods for identification and uses thereof

Also Published As

Publication number Publication date
EP2718435A1 (en) 2014-04-16
JP2014519311A (ja) 2014-08-14
US9187556B2 (en) 2015-11-17
CN103620033A (zh) 2014-03-05
US20140178409A1 (en) 2014-06-26
AU2012265677A1 (en) 2014-01-16
TW201302800A (zh) 2013-01-16
MX2013014489A (es) 2014-03-27
RU2013158399A (ru) 2015-07-20
IL228995A0 (en) 2013-12-31
WO2012169200A1 (en) 2012-12-13
CA2838633A1 (en) 2012-12-13
EP2718435A4 (en) 2014-11-26
SG195047A1 (en) 2013-12-30
KR20140026543A (ko) 2014-03-05

Similar Documents

Publication Publication Date Title
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
EP3556857A3 (en) Cdc45l peptides and vaccines including the same
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
BR112012024997A2 (pt) peptídeos ect2 e vacinas incluindo os mesmos
BR112012022641A2 (pt) peptídeos hjurp e vacinas que incluem os mesmos
MX2020011794A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
TH158366A (th) Topk เปปไทด์ และวัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]